Gyre Therapeutics, Inc. GYRE Noncontrolling interests in subsidiaries
Noncontrolling interests in subsidiaries at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s noncontrolling interests in subsidiaries.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s noncontrolling interests in subsidiaries?
- Gyre Therapeutics, Inc. (GYRE) reported noncontrolling interests in subsidiaries of $35.68M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s noncontrolling interests in subsidiaries changed year-over-year?
- Gyre Therapeutics, Inc.'s noncontrolling interests in subsidiaries decreased by 1.4% year-over-year, from $36.18M to $35.68M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s noncontrolling interests in subsidiaries?
- Over 3 years (2022 to 2025), Gyre Therapeutics, Inc.'s noncontrolling interests in subsidiaries has grown at a 6.9% compound annual growth rate (CAGR), from $29.7M to $36.25M.
- What does noncontrolling interests in subsidiaries mean?
- This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.